Despite the current reliance on the PD-L1 tumor proportion score (TPS) for selecting immunotherapy in NSCLC [7], no universally validated biomarkers exist for routine clinical use to predict treatment outcomes reliably [6,23]. Here, CD274 is linked to non-small cell lung carcinoma.